Product Images Levetiracetam

This is a description for Levetiracetam Tablets, USP. Each tablet contains Levetiracetam, USP 1000 Mg. The usual dosage can be found in the package insert. The pharmacist must dispense in a light-resistant container with a child-resistant closure, and provide the Medication Guide. The tablets should be stored at 20° to 25°C (68° to 77°F), with excursions permitted between 15° to 30°C (59° to 86°F). The Medication Guide can be accessed online at the Rising Pharma website. The product is manufactured in India for Rising Pharma Holdings, Inc.*

This text contains information about a medication with the NDC 64980.605.12, which is Levetiracetam 500 mg tablets. The normal dosage is available in the package insert. It should be stored at 20°C to 25°C with excursions permitted between 15°C to 30°C. The medication should be dispensed in a tight, light-resistant container with a child-resistant closure. It also mentions to provide a Medication Guide and dispense with it available online. This medication is manufactured for Rising Pharma Holdings, Inc., and the text was issued in February 2024.*

This is a description of Levetiracetam tablets in 750 mg strength. It includes information such as storage recommendations, dosage details, and instructions for pharmacists. The tablets should be dispensed in a light-resistant container and stored at a temperature range of 20° to 25°C (68° to 77°F). Pharmacists are reminded to include a Medication Guide when dispensing to patients. The tablets are manufactured in India by Rising Pharma Holdings, Inc. The NDC for these tablets is 64980-606-12.*

This text provides information on Figure 1, showing the Responder Rate with a 250% Reduction from Baseline in Study 1. The data includes percentages ranging from 0% to 39.6%, with statistically significant results against placebo indicated.*

This excerpt discusses the Responder Rate (250% Reduction from Baseline) in Study 2: Period A. The data shows percentages related to the response rate among patients including the placebo group and those taking different doses of Levetiracetam. A statistically significant difference is noted for one of the doses compared to placebo. The information is part of a study evaluating the effectiveness of Levetiracetam.*

This is a figure showing the Responder Rate (>50% Reduction from Baseline) in Study 3. The graph displays percentages ranging from 0% to 45%. The study involved a placebo group with 104 participants and a group taking Levetiracetam 3000 mg/day with 180 participants. The results indicate a statistically significant difference in responder rates between the two groups.*

This text provides data on the Responder Rate (50% Reduction from Baseline) in Study 4, comparing the results for the placebo group (N=97) and the levetiracetam group (N=101). The levetiracetam group showed a statistically significant improvement compared to the placebo group, with responder rates of 44.6% and 45%, respectively.*

This text provides information on the Responder Rate for all patients aged 1 month to less than 4 years with over 50% reduction from baseline in Study 5. The study compares a medication (Lovetracatam) to a placebo and indicates that Lovetracatam showed statistically significant results compared to the placebo group.*

This text describes a figure showing the Responder Rate (250% Reduction from Baseline) in primary generalized tonic-clonic (PGTC) seizure frequency per week in Study 7. The graph indicates the percentage of patients who responded to treatment in terms of seizure reduction from baseline. Levetiracetam is shown to be statistically significant compared to placebo in reducing PGTC seizure frequency.*